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Abstract
Background: The classical functions of the skeleton encompass locomotion, protection and mineral homeostasis.
However, cell-specific gene deletions in the mouse and human genetic studies have identified the skeleton as a
key endocrine regulator of metabolism. The bone-specific phosphatase, Phosphatase, Orphan 1 (PHOSPHO1), which
is indispensable for bone mineralisation, has been recently implicated in the regulation of energy metabolism in
humans, but its role in systemic metabolism remains unclear. Here, we probe the mechanism underlying metabolic
regulation by analysing Phospho1 mutant mice.
Results: Phospho1−/− mice exhibited improved basal glucose homeostasis and resisted high-fat-diet-induced weight gain
and diabetes. The metabolic protection in Phospho1−/− mice was manifested in the absence of altered levels of osteocalcin.
Osteoblasts isolated from Phospho1−/− mice were enriched for genes associated with energy metabolism and diabetes;
Phospho1 both directly and indirectly interacted with genes associated with glucose transport and insulin receptor signalling.
Canonical thermogenesis via brown adipose tissue did not underlie the metabolic protection observed in adult Phospho1−/−
mice. However, the decreased serum choline levels in Phospho1−/− mice were normalised by feeding a 2% choline rich diet
resulting in a normalisation in insulin sensitivity and fat mass.
Conclusion:We show that mice lacking the bone mineralisation enzyme PHOSPHO1 exhibit improved basal glucose
homeostasis and resist high-fat-diet-induced weight gain and diabetes. This study identifies PHOSPHO1 as a potential bone-
derived therapeutic target for the treatment of obesity and diabetes.
Keywords: PHOSPHO1, Osteocalcin, Choline, Bone, Energy metabolism, Insulin, Endocrine organ, Skeleton, Obesity
Background
In addition to its classical structural functions, the skeleton
is a site of significant glucose uptake and is involved in the
regulation of whole-body glucose metabolism [1–9].
Osteocalcin (OCN) is the most abundant osteoblast-
specific non-collagenous protein derived from bone and is
thought to maintain the mechanical properties of the bone
matrix by regulating calcium binding when fully carboxyl-
ated (GLA13-OCN) [10]. However, when OCN is not γ-
carboxylated (uncarboxylated (GLU-OCN) or undercar-
boxylated (GLU13-OCN)), it is released from bone into
the circulation where it is able to regulate whole-body glu-
cose metabolism in an endocrine manner [7, 11–14]. Mice
deficient in OCN have increased fat mass and are hyper-
glycemic, hypoinsulinemic and insulin-resistant in muscle.
Furthermore, serum GLU17-OCN (human form of
GLU13) levels and β-cell function show an inverse
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correlation with glycated haemoglobin (HbA1c), fat mass
and plasma glucose levels [15–19]. Osteoblasts regulate
glucose metabolism through OCN-dependent and inde-
pendent mechanisms [20, 21]. An alternative candidate is
the bone-specific cytosolic phosphatase, Phosphatase, Or-
phan 1 (PHOSPHO1) [22–29]. PHOSPHO1 initiates bone
matrix mineralisation, and PHOSPHO1 deficiency causes
significant skeletal pathology, bowed long bones, osteomal-
acia and scoliosis in early life [30–33]. Within the osteo-
blast, PHOSPHO1 forms choline and inorganic phosphate
(Pi) from the hydrolyses of phosphocholine (PCho). The
liberated Pi is incorporated into hydroxyapatite during the
mineralisation process whereas the choline may alter glu-
cose homeostasis. Elevated levels of choline result in insu-
lin resistance in mice, and choline supplementation
induces hyperglycaemia and insulin intolerance in mice via
the modulation of plasma glucagon [34].
A number of recent studies have implicated PHOS-
PHO1 in the regulation of energy metabolism in humans
[35–38]. Within the PHOSPHO1 gene, differential
methylation sites have been identified as potentially use-
ful biomarkers for clinical application in the early detec-
tion of type 2 diabetes [35] and significant associations
between methylation at loci within the PHOSPHO1 gene
and the future risk of type 2 diabetes exist [36, 37]. Dif-
ferential methylation in PHOSPHO1 was associated with
three lipid traits (total cholesterol, high-density lipopro-
tein cholesterol, and triglycerides) [39, 40]. Most re-
cently, genetic variants of PHOSPHO1 in a bivariate
twin study were found to be associated with body mass
index and waist-hip ratio [38]. Taken together, these
findings suggest that in addition to the established role
of PHOSPHO1 in biomineralisation of the skeleton and
dentition, Phospho1 ablation may result in improved glu-
cose homeostasis and a reduction in metabolic disease
susceptibility. We hypothesised that bone-derived cho-
line may be an important regulator of global metabol-
ism. To address this, we examined the metabolic
phenotype of juvenile and adult Phospho1−/− mice.
Results
Phospho1 inactivation improves glucose tolerance and
insulin sensitivity in juvenile mice
Growth of Phospho1−/− mice was decreased compared to
wild-type (WT) mice (Fig. 1a). Juvenile Phospho1−/− mice
(35-day-old) had reduced body weight and blood glucose
levels (WT, 9.31 ± 0.31mmol/L; Phospho1−/−, 7.76 ± 0.32
mmol/L; p < 0.01) (Fig. 1b, c), improved glucose tolerance
(Fig. 1d) and whole body insulin sensitivity compared to
WT counterparts (Fig. 1e). Consistent with this, adipose
depots were smaller in Phospho1−/− mice: inguinal (iWAT;
WT, 4.31 ± 0.27mg/g; Phospho1−/−, 2.58 ± 0.20mg/g; p <
0.001), mesenteric (mWAT; WT, 5.30 ± 0.30mg/g; Phos-
pho1−/−, 3.39 ± 0.40mg/g; p < 0.01) and gonadal (gWAT;
WT, 4.31 ± 0.27mg/g; Phospho1−/−, 2.58 ± 0.20mg/g; p <
0.001) adipose tissue (Fig. 1f). Phospho1−/− mice had sig-
nificantly smaller livers (WT, 64.36 ± 0.49mg/g; Phos-
pho1−/−, 52.71 ± 3.37mg/g; p < 0.05), and quadriceps (WT,
6.39 ± 0.36mg/g; Phospho1−/−, 5.01 ± 0.26mg/g; p < 0.01)
(Fig. 1g). Food intake (WT, 0.13 ± 0.01 g/gBW/day; Phos-
pho1−/−, 0.12 ± 0.01 g/gBW/day) (Fig. 1i), activity (Add-
itional file 1: Fig. S1) and energy expenditure (day and
night respiratory exchange rate (RER)) (Fig. 1j) were com-
parable between genotypes.
Phospho1 deficiency protects from diet-induced diabetes
in adult mice
We next fed WT and Phospho1−/− mice a chronic high fat
diet (HFD) from weaning until adulthood (120 days of
age). Adult Phospho1−/− mice maintained a lower body
weight when fed the HFD compared to WT HFD mice
(control diet (CD)—WT, 34.20 ± 1.12 g; Phospho1−/−,
28.30 ± 0.59 g; HFD—WT: 38.0 ± 1.54 g, Phospho1−/−:
32.4 ± 1.26 g; p < 0.05; Fig. 2a). Fasting glucose levels were
raised in WT mice fed a HFD but not in Phospho1−/− mice
(CD—WT, 9.50 ± 0.37mmol/l; Phospho1−/−, 8.59 ± 0.27
mmol/l; HFD—WT, 10.3 ± 0.53mmol/l; Phospho1−/−,
9.27 ± 0.77) (Additional file 2: Fig. S2).
Glucose tolerance was improved in Phospho1−/− mice
after chronic HFD (Fig. 2b). Insulin secretion across the
glucose tolerance test (GTT) was also lower in Phos-
pho1−/− mice on both CD and HFD, suggestive of insulin
sensitisation rather than exaggerated β-cell insulin secre-
tion as the major basis of the phenotype (Fig. 2c). This
was confirmed with insulin tolerance tests (ITT) after
chronic HFD, which revealed greater glucose disposal in
Phospho1−/− mice (Fig. 2d–f).
Phospho1 deficiency protects from diet-induced obesity
in adult mice
The insulin sensitivity observed in Phospho1−/− mice was
consistent with the finding of smaller inguinal (CD—
WT, 4.51 ± 0.37 mg/g BW; Phospho1−/−, 2.79 ± 0.42 mg/g
BW; HFD—WT, 14.67 ± 2.12 mg/g BW, Phospho1−/−,
7.95 ± 1.56 mg/g BW; p < 0.01), mesenteric (CD—WT,
13.2 ± 1.34 mg/g BW; Phospho1−/−, 5.56 ± 1.61 mg/g BW;
HFD—WT, 24.14 ± 4.05 mg/g BW; Phospho1−/−, 10.22 ±
1.57 mg/g BW; p < 0.01) and gonadal (CD—WT, 13.7 ±
1.81 mg/g BW; Phospho1−/−, 6.96 ± 0.58 mg/g BW;
HFD—WT, 28.77 ± 3.12 mg/g BW; Phospho1−/−, 18.78 ±
2.37 mg/g BW; p < 0.01) fat depots noted in CD and
HFD Phospho1−/− mice at necropsy (Fig. 3a). Moreover,
confirmation that Phospho1−/− mice did not become
obese when fed a HFD was shown by μMRI (Add-
itional file 3: Fig. S3). These observations were also not
explained by altered activity or increased food intake in
120-day-old adult male mice (data not shown).
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Fig. 1 Juvenile Phospho1−/− mice display increased insulin sensitivity and decreased fat mass. Phospho1−/− mice showed decreased (a, b) growth and live
weight at 35 days of age and (c) fasting glucose, (d, e) improved glucose and insulin tolerance and (f) decreased adipose tissue. Notable differences in tissue
mass were also observed in the liver, quadriceps and spleen. These changes were not a consequence of (i) altered food intake or (j) energy expenditure. Data
in (a) and are shown as mean± SEM of 16–17 mice per group, (b) mean± SEM 6–8 mice per group. *p <0.05, **p <0.01, ***p <0.001 and the data were
assessed as follows: (a, d, e) repeated measures two-way ANOVA with Sidak’s multiple comparisons test; (b, c) two-tailed t test; (f, g) two-tailed unpaired t test;
(i) two-tailed Mann–Whitney test; (j) two-tailed unpaired t test
Fig. 2 Phospho1−/− mice are protected from glucose intolerance. a Body mass. b Glucose tolerance test (GTT). c Glucose stimulate insulin secretion
(GSIS). d Insulin tolerance test (ITT). e Incremental area under the curve for GTT. f HOMA-IR. All data are shown as mean ± SEM. b–e 5–8 mice per
group. Different letters above the error bar show significant difference at p < 0.05 and the data were assessed as follows: a, e, f Two-way ANOVA with
multiple comparisons; b–d repeated measures two-way ANOVA with Sidak’s multiple comparisons test
Suchacki et al. BMC Biology          (2020) 18:149 Page 4 of 20
Histological analysis revealed smaller gonadal adipo-
cytes in Phospho1−/− mice fed both a CD and a HFD.
High fat feeding had no significant effect on gonadal adi-
pocyte size in Phospho1−/− mice; however, it significantly
increased the number of large adipocytes (> 60 μm in
diameter) in WT mice (p < 0.0001) (Fig. 3b). Phospho1−/−
mice were also protected from the pronounced hepatic
fat accumulation that was noted in WT mice following
HFD feeding (Fig. 3c, d).
Insulin sensitivity in Phospho1−/− mice is independent of
elevated adiponectin serum levels
In an attempt to uncover the mechanism(s) responsible
for the increased insulin sensitivity in Phospho1−/− mice,
serum levels of adiponectin and leptin were measured.
Levels of high molecular weight adiponectin, a hormone
linked to insulin-sensitisation [41], were decreased in
Phospho1−/− mice fed either a CD (2.62-fold) or a HFD
(1.92-fold) (both p < 0.001) suggesting that insulin
sensitivity and protection from obesity are independent
of adiponectin (Fig. 4a). The observed decrease in circu-
lating adiponectin in Phospho1−/− mice was not due to
decreased bone marrow adipose tissue, an endocrine
organ that contributes significantly to serum adiponectin
(Additional file 4: Fig. S4) [42].
Serum leptin levels in CD-fed mice were unaffected by
Phospho1 deficiency, whereas in comparison to WT
mice fed a HFD serum leptin levels were significantly
decreased 1.31-fold (p < 0.05) in Phospho1−/− mice fed a
HFD (Fig. 4b), accordant with reduced fat mass [43].
Phospho1−/− CD mice had increased circulating serum
triglycerides compared to WT CD mice, but no change
was observed in WT and Phospho1−/− mice fed a HFD
(Fig. 4c). Consistent with increased oxidative metabolism
of carbohydrate and lipids in other peripheral tissues,
mRNA levels of genes encoding key metabolic proteins
were increased in adipose tissue (Lpl) muscle (Fndc5)
and liver (Prkaa1, Pepck1 and Ppara) (Fig. 4d-f). The
Fig. 3 Phospho1−/− are protected from NAFLD. a Fat analysis of 120-day-old WT and Phospho1−/− mice on both a control and HFD. b Quantification of
gonadal fat adipocyte diameter. c Quantitative assessment of liver fat utilising spectroscopy. d Gross livers of representative mice left to right (WT, WT HFD,
Phospho1−/−, Phospho1−/− HFD; scale bar = 10mm). All data are represented as mean± S.E.M. b, c n =3–4 mice per group. *p <0.05. Different letters above the
error bar show significant difference at p< 0.05 and the data were assessed as follows: a–c Two-way ANOVA with multiple comparisons
Suchacki et al. BMC Biology          (2020) 18:149 Page 5 of 20
Fig. 4 (See legend on next page.)
Suchacki et al. BMC Biology          (2020) 18:149 Page 6 of 20
mRNA levels of genes encoding GLUT receptors
(Slc2a1, 2, 4, 10 and 12) were largely unchanged
(Fig. 4g-i).
Canonical thermogenesis does not underlie the metabolic
protection observed in adult Phospho1 deficient mice
Thirty-five-day-old Phospho1−/− mice had decreased
interscapular brown adipose tissue (BAT) mass com-
pared to WT counterparts (WT, 5.11 ± 0.57 mg/g; Phos-
pho1−/−, 3.05 ± 0.40 mg/g; p < 0.01) (Fig. 5a). However
this reduction in BAT mass did not persist to adulthood
nor during high-fat feeding (Fig. 5b). Strikingly, adult
and high-fat-fed Phospho1−/− mice had smaller brown
adipocytes compared to WT controls (Fig. 5c). In order
to see if BAT activation and thermogenesis might be re-
sponsible for the observed phenotype, we measured key
brown fat genes including uncoupling protein 1 (Ucp1)
(Fig. 5d, e); no differences were observed in the mRNA
and protein levels. Furthermore, there were no signifi-
cant differences in respiratory exchange ratio (RER, indi-
cative of metabolic substrate preference) or energy
expenditure between WT or Phospho1−/− mice fed either
a chow or HFD housed at either room temperature or
during cold exposure (4 °C) (Fig. 5f-i). These in vivo data
show that increased canonical thermogenesis does not
underlie the metabolic protection observed in the Phos-
pho1-deficient mice so this line of investigation was not
pursued further.
Diabetes mellitus-associated genes are enriched in
Phospho1−/− primary osteoblasts
We next sought to unravel the genetic circuitry respon-
sible for the improved glucose tolerance in Phospho1−/−
mice. To address this, a transcriptomic analysis of Phos-
pho1-deficient osteoblasts was completed. There was a
striking 20-fold upregulation of embryonic stem cell
phosphatase (Esp) mRNA, the gene encoding the protein
osteotesticular protein tyrosine phosphatase (OST-PTP)
in Phospho1-deficient mice [7]. These data were vali-
dated in primary WT and Phospho1−/− calvarial osteo-
blasts and Phospho1-deficient osteoblast overexpressing
Phospho1 (Fig. 6a, b). Protein tyrosine phosphatases are
recognised master regulators of insulin receptor signal-
ling (INSR), negatively modifying osteoblast-insulin sig-
nalling and thereby controlling GLU13-OCN release [7,
44–48]. The identification of elevated Esp expression in
Phospho1−/− mice was strongly suggestive of a reciprocal
regulation between OST-PTP and PHOSPHO1 in the
control of glucose homeostasis. This increased Esp ex-
pression was however inconsistent with the improved
glucose tolerance in the Phospho1−/− mice. Therefore in
an attempt to reconcile this anomaly, we measured cir-
culating GLU–OCN and GLU13-OCN, which were
found to be unchanged in juvenile and adult Phos-
pho1−/− mice (Fig. 6c). Only GLU–OCN and GLU13-
OCN present in the serum have been shown to act as a
hormone [5, 49]. Therefore, these data implied that ele-
vated serum levels of uncarboxylated or undercarboxy-
lated OCN did not mediate the improved metabolic
phenotype (Fig. 6c, d). The elevated levels of carboxyl-
ated and total OCN in Phospho1 deficiency was consist-
ent with increased bone turnover in these mice as
previously reported [30].
Phospho1−/− calvarial osteoblasts show a greater
metabolic capacity in utilising exogenous substrates
compared to WT osteoblasts
Primary calvarial osteoblast metabolism analysis revealed
that differentiated Phospho1−/− osteoblasts had elevated
basal and FCCP (protonophoric uncoupler) induced oxy-
gen consumption rates (indicative of oxidative phos-
phorylation) compared to WT osteoblasts when supplied
exogenously with glucose, pyruvate and glutamine (Add-
itional file 5: Fig. S5). There was a significant increase in
the glycolytic rate of both the non-differentiated and dif-
ferentiated Phospho1−/− osteoblasts compared to WT os-
teoblasts suggesting that they have increased glucose
metabolism. Based on these observations, we conclude
that differentiating Phospho1−/− calvarial osteoblasts
show a greater metabolic capacity in utilising exogenous
substrates compared to WT osteoblasts.
To further clarify the genetic pathways underpinning
these observations, 22 differentially expressed genes
identified from the microarray analysis were found by
Ingenuity Pathway Analysis (IPA) to be associated with
glucose homeostasis (Additional file 6: Table. S6). Fur-
ther predictive analysis of the differentially expressed
genes of the original microarray data set identified > 40
genes to be associated with energy metabolism (p =
1.04 × 10−6) (Fig. 7a) of which 10 were found to be asso-
ciated with both diabetes and bone, following an NCBI
(PubMed) in silico search. Validation by RT-qPCR con-
firmed that 70% of the genes predicted by IPA (Vdr,
Slc1a3, Adamts4, Cd68, Cfp, Fmod and Lum) were
(See figure on previous page.)
Fig. 4 Phospho1−/− mice are insulin sensitive despite decreased adiponectin. a Adiponectin, b leptin and c triglyceride serum quantification. RT-
qPCR analysis of tissue extracted from 120-day-old WT and Phospho1−/− mice, d adipose tissue, e quadriceps femoris and f liver. RT-qPCR analysis
of GLUT receptors from g adipose tissue, h quadriceps femoris and i liver. Data are represented as mean ± S.E.M. * p < 0.05. Different letters above
the error bar show significant difference at p < 0.05 and the data were assessed as follows: a–c Two-way ANOVA with multiple comparisons, d–i
two-tailed Mann–Whitney test for non-normally distributed data and two-tailed unpaired t test for normally distributed data
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differentially regulated in Phospho1-deficient osteoblasts
(p < 0.05; Fig. 7b and Additional file 7: Table. S7). Fur-
thermore, GeneMANIA network analysis predicted that
Phospho1 both directly and indirectly interacts with 36
genes associated with glucose transport and metabolic
processes and insulin receptor signalling (Add-
itional file 8: Fig. S8). Of the output genes, Atf4, Foxo1
and Insr are recognised skeletal modulators of energy
metabolism, suggesting crosstalk between Phospho1 and
other metabolic regulatory genes [5, 50, 51].
Identification of differentially expressed serum proteins in
Phospho1−/− mice
To explore the secretome profile, quantitative SWATH
(sequential window acquisition of all theoretical spectra)
MS (mass spectrometry) proteomics [52] was conducted
on serum from WT and Phospho1−/− mice fed CD and
HFD. Differentially expressed proteins (> 100) were iden-
tified in HFD Phospho1−/− serum compared to HFD-fed
WT mice. These proteins were highly associated with
glycolysis, gluconeogenesis and ‘metabolic pathways’
(See figure on previous page.)
Fig. 5 Canonical thermogenesis does not underlie the metabolic protection observed in the adult Phospho1-deficient mice. Brown adipose tissue
(BAT) mass in a juvenile (35-day-old) and b adult (120-day-old) WT and Phospho1−/− mice. c Representative micrographs of BAT from WT and
Phospho1−/− mice. d Brown fat gene expression and e UCP1 protein analysis. f–i Insulin sensitivity and protection from diet induced obesity in
Phospho1−/− mice was not a consequence of altered energy expenditure (RER—respiratory exchange ratio; H4 = H3 (W)/lean mass (kg)). Data are
represented as mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001. Different letters above the error bar show significant difference at p < 0.05 and
the data were assessed as follows: a, d two-tailed Mann–Whitney test. b, d, f–i Two-way ANOVA with multiple comparisons
Fig. 6 Osteocalcin-independent mechanism of PHOSPHO1-regulated energy metabolism. To assess the relative change in Esp mRNA expression
in primary calvarial osteoblasts, RT-qPCR was conducted to compare a primary WT and Phospho1−/− osteoblasts and b Phospho1−/− osteoblast
transfected with empty (EV) or overexpressing (OE) vectors. c, d Osteocalcin content of serum from WT and Phospho1−/− mice at 60 and 120 days
of age. Data are represented as mean ± S.E.M n = 5–6 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 and the data were assessed as follows:
a–c Two-tailed Mann–Whitney test or two-tailed unpaired t test
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(Additional file 9: Table. S9). Pathway and network ana-
lysis predicted that the identified proteins interacted
with miR-34a, a microRNA that is known to affect di-
verse parts of insulin signalling in the pancreas, liver,
muscle and adipose tissue [53].
Bone-derived choline is involved in global energy
regulation
Neutral sphingomyelinase 2 (nSMase2) catalyses the hy-
drolysis of sphingomyelin to form ceramide and PCho
[54]. Furthermore, PCho is the preferred substrate for
PHOSPHO1 yielding choline and Pi (Fig. 8a) [55]. As el-
evated levels of both ceramide and choline result in in-
sulin resistance in mice [34, 56] we targeted these
intermediates to establish if alterations in their serum
levels could explain the insulin sensitive phenotype in
Phospho1−/− mice [34, 56]. The levels of various cer-
amide species were unchanged (Fig. 8b); however, Phos-
pho1−/− mice had a significant decrease in serum choline
levels (WT, 0.152 ± 0.001 μg/ml; Phospho1−/−, 0.128 ±
0.003 μg/ml; p < 0.01) (Fig. 8c) which were normalised
upon choline supplementation. Supplementation of WT
and Phospho1−/− mice with a 2% choline diet (a well-
tolerated, palatable diet [57]), also normalised the insulin
sensitivity measured in Phospho1−/−, measured by GTT
(Fig. 8d). However, unlike WT mice which when fed a
2% choline diet took longer to recover from the insulin
challenge, Phospho1−/− showed no metabolic change in
response to insulin between the diets (Fig. 8e). Further-
more, choline supplementation normalised the lean
phenotype observed in Phospho1−/− mice (Fig. 8f, g).
These results support the notion that Phospho1 defi-
ciency improves the metabolic profile of mice in vivo
and confers resistance to obesity and diabetes in part via
the alteration of serum choline levels.
Discussion
The fundamental observations presented in this study
further strengthen the concept that the skeleton acts as
an endocrine organ and provides empirical evidence for
a critical role for PHOSPHO1 in energy metabolism.
Phospho1 deficiency results in decreased blood glucose
levels, improved insulin sensitivity, glucose tolerance and
conferred protection from diet-induced obesity and dia-
betes in mice despite a 60-fold upregulation of Esp
expression by Phospho1−/− osteoblasts. Mice lacking Esp
in osteoblasts present with severe hypoglycaemia and
hyperinsulinemia resulting in postnatal lethality in the
first 2 weeks of life [7]. Conversely, mice overexpressing
Esp exclusively in osteoblasts were glucose intolerant
and insulin resistant [7, 44–48]. Intriguingly, the in-
creased insulin sensitivity in Phospho1−/− mice was not
associated with the expected rise in serum GLU13-OCN
levels suggesting that PHOSPHO1-regulated energy me-
tabolism is via OCN-independent mechanisms. This no-
tion has previously been observed when partial genetic
ablation of osteoblasts profoundly affected energy ex-
penditure, gonadal fat weight and insulin sensitivity
which were not restored by the administration of OCN
[20, 21]. Nevertheless, it is possible that the increased in-
sulin sensitivity noted in Phospho1−/− mice may be
primed by an initial rise in GLU13-OCN levels, which is
eventually normalised in a compensatory manner by the
observed increase in Esp expression. This being the case
we would predict that the loss of Esp on a Phospho1−/−
background would exacerbate the insulin sensitivity due
to increased GLU13-OCN serum levels. These data
strengthen the concept that a novel pathway exists be-
tween osteoblasts and glucose homeostasis; however, it
does highlight the potential cross-talk between OCN-
dependent and OCN-independent mechanisms of glu-
cose metabolism.
The role of PHOSPHO1 in controlling bone mineral-
isation has been extensively investigated through the use
of both in vitro and in vivo mouse models. Crucial for
the initiation of mineralisation within matrix vesicles,
PHOSPHO1 hydrolyses membrane lipid derivatives, pri-
marily PCho to produce Pi (utilised in hydroxyapatite
formation) and choline [55]. Phosphocholine can be
formed from choline via choline kinase activity or phos-
phatidylcholine via PLA2 and ENPP6 as well as from the
hydrolysis of sphingomyelin, via nSMase2 to form PCho
and ceramide [58]. Mindful of this, it has been reported
that elevated levels of both ceramide and choline result
in insulin resistance in mice [34, 56]. We saw no change
in ceramide species in Phospho1−/− mice; however, there
was a significant decrease in serum choline levels in
Phospho1−/− mice, which was normalised in Phospho1−/−
mice fed a 2% choline rich diet resulting in a normalisa-
tion in insulin sensitivity and fat mass. This study
(See figure on previous page.)
Fig. 7 Ingenuity Pathways Analysis network summary predictions. a Ingenuity Pathways Analysis was used to predict further genes associated
with glucose homeostasis based upon the 22 genes found to be differentially expressed in the microarray. b Predicated genes were analysed by
RT-qPCR in WT and Phospho1−/− primary calvarial osteoblast’s. Results were normalised to the Atp5b housekeeping gene. Data are represented as
mean ± S.E.M (n = 3 replicates). *P < 0.05, **P < 0.01, ***P < 0.001. Red = Upregulated. Green = Downregulated (the darker the shade of green and
red colour indicates a more extreme up/down regulation, conversely the paler the shade indicates a more subtle up/down regulation. Dashed
line = indirect interaction (blue = inhibition, yellow = findings underlying the relationship are inconsistent with the state of the downstream node,
grey = Ingenuity Pathways Analysis prediction) and the data were assessed in (b) using a two-tailed unpaired t test
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Fig. 8 (See legend on next page.)
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highlights for the first time the importance of bone-
derived choline in the regulation of energy metabolism;
however, it remains clear that choline supplementation
alone does not fully correct all metabolic defects in
Phospho1−/− mice.
The regulation of global energy metabolism by the
skeleton is a complex, multifactorial process, and it is
therefore likely that presently undefined bone secreted
factors may have a significant role in PHOSPHO1’s abil-
ity to regulate global energy. We identified > 100 se-
creted proteins that may contribute to the energy
regulation via the skeleton. These unique proteins were
highly associated with glycolysis, gluconeogenesis and
‘metabolic pathways’ and association with miR-34a, a
microRNA that affects diverse parts of insulin signalling
in the pancreas, liver, muscle and adipose tissue [53, 59].
Furthermore, lumican, a proteoglycan secreted by differ-
entiating osteoblasts and a constituent of the bone
matrix was found to be enriched in serum of Phos-
pho1−/− mice by both proteomic and microarray analysis.
Interestingly, lumican has also been observed in the de-
cidua of diabetic patients [60, 61]. Further investigations
of these and other candidates may uncover new skeletal
regulators of energy metabolism that act via osteocalcin
independent mechanisms.
The metabolic phenotype observed in the Phospho1-
deficient mice was not due to increased BAT activation
despite striking histological differences between WT and
Phospho1−/− tissue. BAT is a thermogenic organ that in-
creases energy expenditure to generate heat, maintaining
body temperature in a cold environment [62]. When
activated by cold exposure or through activation of β3-
adrenergic receptors, BAT improves insulin sensitivity
and lipid clearance, highlighting its key role in metabolic
health [63]. PHOSPHO1 has been previously suggested
to have a role in murine BAT function. Increased ex-
pression of Phospho1 in both isolated brown and white
adipocytes was observed following treatment with the β-
adrenergic agonist (CL316,243) compared to placebo-
treated white adipocytes [64]. Mice with an adipose-
specific defect in fatty acid oxidation (Cpt2A−/−) showed
a loss of β3-adrenergic induced Phospho1 expression in
BAT [64] and expression of Phospho1 was shown to be
elevated in Ucp1-deficient animals; however, WT mice
had very low Phospho1 expression in BAT and no de-
tectable PHOSPHO1 was observed in WT iWAT and
BAT [65]. No difference in Phospho1 gene expression
was observed between human supraclavicular and sub-
cutaneous adipose progenitor cells (GEO Dataset:
GDS5171/8016540) and murine WAT had elevated
Phospho1 gene expression compared to BAT (GEO
Dataset: GDS2813/1452485_at). In our hands, we have
noted high expression of Phospho1 in murine BAT but
no protein expression was detected (Additional file 10:
Fig. S10). Taken together, these data suggest that Phos-
pho1 is likely to play a role in BAT function; however,
the BAT phenotype observed in Phospho1 deficient mice
does not appear to underlay the metabolic protection we
see in these animals. Further studies are necessary to un-
ravel the role of PHOSPHO1 in BAT using a BAT con-
ditional knock-out model of Phospho1.
Conclusions
Collectively, the results of this study add further credibil-
ity to the concept that GLU13-OCN is not the sole me-
diator of the endocrine function of the skeleton [20]. We
suggest, as others have, that further undefined bone-
derived proteins/lipids work in partnership with OCN to
regulate the metabolic function of the skeleton and
affect other metabolic organs such as muscle and liver
[20]. Indeed, this study has identified other potential
protein mediators and raised the possibility that bone-
derived choline may contribute to the regulation of the
development of the metabolic syndrome. Furthermore,
our results suggest that Esp may act as a fine controller
of insulin sensitivity in mice, offering protection from se-
vere hypoglycaemia and dyslipidaemia.
Several previous reports have suggested an association
between PHOSPHO1 expression in disorders of altered
energy metabolism such as obesity and diabetes [35–39].
The data from this present study is both supportive of
such an association but also provides insight into the
mechanisms by which PHOSPHO1 may contribute to
the regulation of energy metabolism, inclusive of insulin
sensitivity, glucose tolerance and fat metabolism. Also,
inhibitors of PHOSPHO1 activity such as the proton
pump inhibitor lansoprazole, commonly prescribed to
control and prevent symptoms of gastroesophageal re-
flux disease and dyspepsia, have been associated with
improved glycaemic control in diabetic patients [28, 66–
68]. Taken together, the identification of PHOSPHO1 in
the role of energy metabolism in both the human and
(See figure on previous page.)
Fig. 8 Bone derived choline regulates insulin sensitivity. a Schematic diagram outlining the mechanisms by which ceramide and choline and
linked. b Mouse serum ceramide and choline (c) analysis by LC-MS/MS (ceramide) and assay (choline). d GTT. e ITT. f Dissected fat depot weights.
g Quantification of epididymal fat adipocyte diameter and representative histology. Data are represented as mean ± S.E.M (c–g) n = 3–5 per
group. Different letters above the error bar show significant difference at p < 0.05 and the data were assessed as follows: c, f, g Two-way ANOVA
with multiple comparisons. b One-way ANOVA with Dunnet’s or Tukey’s tests for multiple comparisons. d, e repeated measures two-way ANOVA
with Sidak’s multiple comparisons test
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mouse offers the potential to manipulate key targets of




Examine glucose metabolism and the energy status of
Phospho1−/− mice.
Reagents
All chemicals, tissue culture medium and buffers were
from Sigma-Aldrich (Dorset, UK) and Invitrogen (Paisley,
UK) unless otherwise stated. PCR oligonucleotides were
purchased from MWG Eurofins (Ebersberg, Germany)
and Primer Design (Southampton, UK). PHOSPHO1
HuCAL Fab bivalent antibody was purchased from AbD
Serotech (Kidlington, UK). All antibodies were diluted 1:
1000 unless otherwise noted.
Animals
Phospho1 null mice were generated as previously de-
scribed [31]. Offspring carrying the mutant Phospho1
gene were identified by genotyping (F: 5′-TCCTCCTC
ACCTTCGACTTC-3′, R: 5′-TCCTCCTCACCTTCGA
CTTC-3′). All in vivo studies were conducted at 120
days of age unless otherwise stated. Male mice were fed
a high fat diet consisting of 58% of calories from fat
(DBM Scotland, Broxburn, UK) or control diet (6.2%
calories from fat; Harlan Laboratories, Indianapolis, IN,
USA) starting at 4 weeks of age. Male mice were fed a
2% supplemented choline diet (Harlan Laboratories) or
control diet (Harlan Laboratories) for 5 weeks prior to
cull at 120 days. Ad libitum food consumption was mon-
itored for 6 days and basal nocturnal activity was quanti-
fied using an AM524 Single Layer X, Y IR activity
monitor and associated Amonlite software (Linton In-
strumentations, Norfolk, UK). Juvenile metabolic activity
was measured using indirect calorimetry (Oxymax Lab
Animal Monitoring System: CLAMS (Columbus Instru-
ments, OH USA). Adult metabolic rate was measured
using indirect calorimetry (TSE PhenoMaster 1.0, with
software version 6.1.9). Cold exposed mice were first
housed in these cages for 3 days at room temperature
(RT) for acclimation and baseline measurements. Mice
were then house for 72 h at 4 °C. All experiments were
conducted blind to the operator. Animals were main-
tained under conventional housing conditions with a 12-
h light/dark cycle with free access to food and water (ex-
cept when food was restricted during fasting). All animal
experiments were approved by The Roslin Institute’s
Animal Users Committee, and the animals were main-
tained in accordance with UK Home Office guidelines
for the care and use of laboratory animals.
Metabolic studies
Male juvenile and adult (35 and 120 days old respect-
ively) were weighed and fasted for 4 h between 9 am and
1 pm. Prior to the start of the tests, a basal blood sample
was collected by venesection into EDTA powder-coated
capillary tubes (Starstedt, Leicester, UK). Basal glucose
levels were measured using a glucose monitoring system
(Accu-Chek® Aviva, Roche, Leicester, UK). Two milli-
grammes of D-glucose (Sigma, Poole, UK) per g of body
weight was administered by gavage or 0.5 mU of insulin
(Actrapid, NovoNordisk, Bagsvaerd, Denmark) per g/
body weight was administered intraperitoneally (i.p.). At
precisely 15, 30, 60 and 120 min following administra-
tion, blood glucose was measured with an Accu-Chek®
Aviva glucose meter (Roche Diagnostics Ltd., Lewes,
UK) and insulin was measured by ELISA (ChrystalChem,
Chicago, IL, USA). Animals were allowed to recover for
2 weeks prior to euthanasia. Tissues were collected for
protein, gene and histological analysis.
Serum measurements
Serum samples were prepared from blood collected by
heart puncture of CO2 culled mice in the fasted state.
Total, carboxylated (GLA13-OCN), undercarboxylated
(GLU13-OCN) and uncarboxylated (GLU-OCN) osteo-
calcin [49], adiponectin and leptin (CrystalChem) were
quantified by ELISA.
Primary osteoblast isolation and culture
Under sterile conditions, calvaria were isolated from 2-
to 4-day-old new-born WT and Phospho1−/− mice as
previously described [69]. Osteoblasts were expanded in
flasks in growth medium consisting of α-MEM supple-
mented with 10% FBS and 1% gentamicin in a humidi-
fied atmosphere of 95% air/5% CO2 and maintained at
37 °C. When the cells reached 80–90% confluency, they
were seeded at a density of 2.5 × 104/cm2 in multi-well
plates. Conditioned medium was collected upon plate
confluency, centrifuged to remove particulates and fro-
zen at − 80 °C until required. For overexpression studies,
primary osteoblasts were transfected with empty (EV) or
overexpressing (OE) vectors as previously described [70].
Mito stress test
An XF24 Analyser (Agilent Technologies, Santa Clara,
CA, USA) was used to measure the respiratory function
of primary osteoblasts. Osteoblasts were plated at a
density of 50,000 cells per well and transferred to a
37 °C CO2 incubator until and calvarial osteoblasts were
differentiated using osteogenic differentiation media
containing 8 mM β-glycerophosphate and 50 μg/ml as-
corbic acid for 3 days. On the day of the assay, cells were
washed in XF Assay Media supplemented with 25mM
glucose and 10mM pyruvate and placed in a non-CO2
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Table 1 Sequences of primers used for qPCR
Species Transcript Primer sequences 5′ to 3′
M. musculus Adamts4 F: ATGGCCTCAATCCATCCCAG
R: GCAAGCAGGGTTGGAATCTTTG
M. musculus Adipoq F: GGCCGTTCTCTTCACCTACG
R: TGGAGGAGCACAGAGCCAG
M. musculus Adrb3 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Atgl Primer Design, Southampton, UK; sequence not disclosed
M. musculus Atp5b Primer Design, Southampton, UK; sequence not disclosed
M. musculus Bmp4 F: ATTCCTGGTAACCGAATGCTG
R: CCGGTCTCAGGTATCAAACTAGC
M. musculus Cd68 F: CCATCCTTCACGATGACACCT
R: GGCAGGGTTATGAGTGACAGTT
M. musculus Cfp F: CTGCTACTGGTTATCCTGCCA
R: TCTACCCTGATGTCTCTCCCA
M. musculus Cpt1a Primer Design, Southampton, UK; sequence not disclosed
M. musculus Cxcl14 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Dgat1 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Dgat2 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Esp Primer Design, Southampton, UK; sequence not disclosed
M. musculus Fmod Primer Design, Southampton, UK; sequence not disclosed
M. musculus Fndc5 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Igf1 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Lep F: ATTTCACACACGCAGTCGGTAT
R: GGTGGAGCCCAGGAATGAAG
M. musculus Lpl F: TCTGTACGGCACAGTGG
R: CCTCTCGATGACGAAGC
M. musculus Lum F: CTCTTGCCTTGGCATTAGTCG
R: GGTCATCACAGTACATGGCAGT
M. musculus Mpeg1 F: CTGGATGATAATAGCGTGTGCT
R: AAGACAGGTAGTTTCAGGGCA
M. musculus Pck1 F: CATATGCTGATCCTGGGCATAAC
R: CAAACTTCATCCAGGCAATGTC
M. musculus Phospho1 F: TTCTCATTTCGGATGCCAACA
R: TGAGGATGCGGCGGAATAA
M. musculus Ppara F: CCCTGAACATCGAGTGTCGA
R: AATAGTTCGCCGAAAGAAGCC
M. musculus Ppargc1a F: CCCTGCCATTGTTAAGACC
R: TGCTGCTGTTCCTGTTTTC
M. musculus Prkaa1 Primer Design, Southampton, UK; sequence not disclosed
M. musculus Prkaa2 F: GTCAAAGCCGACCCAATGATA
R: CGTACACGCAAATAATAGGGGTT
M. musculus Slc1a3 F: ACCAAAAGCAACGGAGAAGAG
R: GGCATTCCGAAACAGGTAACTC
M. musculus Slc2a1 F: TCAACACGGCCTTCACTG
R: CACGATGCTCAGATAGGACATC
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incubator at 37 °C for 1 h prior to start of assay. Re-
agents were prepared for the assay (injection volume of
75 μL for each reagent per well) from 2.5 mM Seahorse
stock solutions, Oligomycin (1.2 μM). Following equili-
bration, the Seahorse plate was placed in the Seahorse
XF24 Analyser for sample analysis. The raw data was
normalised to protein content in each well at the end of
the assay [71].
Gene expression analyses and immunoblotting
RNA extractions from tissues and cells were performed
using the RNeasy Lipid Tissue Kit (Qiagen). The Super-
Script First Strand Synthesis System (Invitrogen) was
used for reverse transcription. Real-time PCR amplifica-
tion with the 2 x precision master mix (Primer design,
Southampton, UK) using the Stratagene Mx3000P real-
time QPCR system (Agilent Technologies, Santa Clara,
CA, USA). Each sample was tested in triplicate and com-
pared to a housekeeping gene (Atp5B in osteoblasts and
bone tissue, Lrp10 in adipose tissue and Gapdh in all
other tissues) using MxPro software (Cheshire, UK), and
the relative expression of the analysed genes was calcu-
lated using the ΔΔCT method [72]. All primer se-
quences are described in Table 1. Primers sequences are
available in Table 1. For protein extraction, cells were
scraped and tissues homogenised in an appropriate vol-
ume of radio-immunoprecipitation assay (RIPA) buffer
containing 15% of complete mini protease inhibitor
cocktail (Roche, Burgess Hill, West Sussex, UK). Protein
concentration was determined by the Bio-Rad DC pro-
tein assay (Bio-Rad, Hertfordshire, UK). Immunoblotting
was conducted with specific antibodies and protein
bands were visualised using the enhanced chemilumines-
cence (ECL) Western Blotting Detection System (GE
Healthcare, Chalfont St Giles, UK) or the Odyssey
infrared detection system (LICOR). All antibodies are
described in Table 2.
Tissue histology
Tissue was fixed in 4% PFA and embedded in paraffin
wax. Five-micrometre sections were stained with haema-
toxylin and eosin (H&E) using the Leica Autostainer and
mounted in DePeX (VWR, Lutterworth, UK). Adipocyte
diameter and pancreatic β-cell islet number and size
were quantified using ImageJ software as previously de-
scribed [7, 73].
Osmium staining
Mouse tibiae were fixed in 10% neutral-buffered formalin
and decalcified in 14% EDTA, pH 7.4. Mouse bones were
stained according to [74]. Briefly, bones were stained with
a 1% osmium tetroxide solution for 48 h at room
temperature. Bones were washed in Sorensen’s buffer and
embedded in 1% agarose prior to μCT scanning (μCT100
Scanco Medical, Bassersdorf, Switzerland) − 12 μm,
medium resolution, 70 kVp, 114 μA, 0.5mm AL filter and
integration time 500ms. Analysis was performed using
the manufacturer’s software.
Micro-magnetic resonance, computed tomography and
liver spectroscopy
CD and HFD mice were sacrificed immediately before im-
aging. For micro-magnetic resonance, mice were imaged
on a Varian 7 Tesla magnet using VnmrJ Pre-Clinical
MRI Software. T2-weighted images were acquired both in
the axial (1mm thickness, 192 × 192 pixels, TR – 3000ms,
TE 24ms, 1 average, FOV – 38.4 × 38.4) and coronal
planes (0.5mm thickness, 512 × 256 pixels, TR – 3000ms,
TE 24ms, 4 averages, FOV – 102.4 × 51.2). Liver spectros-
copy was conducted on user defined areas (TR - 1800ms,
TE – 11.5ms, 16 averages, Vauxhall 3x3x3). Lorentzian
Table 1 Sequences of primers used for qPCR (Continued)
Species Transcript Primer sequences 5′ to 3′
M. musculus Slc2a10 F: ACCAAAGGACAGTCTTTAGCTG
R: ATCTTCCAAGCAGACGGATG
M. musculus Slc2a12 F: GGGTGTCAACCTTCTCATCTC
R: CCAAAGAGCATCCCTTAGTCTC
M. musculus Slc2a2 F: TGTGCTGCTGGATAAATTCGCCTG
R: AACCATGAACCAAGGGATTGGACC
M. musculus Slc2a4 F: CCAGTATGTTGCGGATGCTAT
R: TTTTAGGAAGGTGAAGATGAAGAAG
M. musculus Ucp1 F: GGATGGTGAACCCGACAACT
R: AACTCCGGCTGAGAAGATCTTG
M. musculus Vdr F: GAATGTGCCTCGGATCTGTGG
R: ATGCGGCAATCTCCATTGAAG
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and Gaussian lineshape were used to fit peaks to MR data
(jMRUI http://www.mrui.uab.es/mrui/mrui).
Microarray and pathway analysis
Labelled cRNA was prepared from 500 ng of WT and Phos-
pho1−/− primary calvarial osteoblast RNA using the Illu-
mina® RNA Amplification Kit from Ambion (Austin, TX,
USA). The labelled cRNA (1500 ng for mouse and 750 ng
for human) was hybridised overnight at 58 °C to the
SentrixMouseWG-6 Expression BeadChip or humanHT-12
Expression BeadChip (> 46,000 gene transcripts; Illumina,
San Diego, CA, USA) according to the manufacturer’s in-
structions. BeadChips were subsequently washed and devel-
oped with fluorolink streptavidin-Cy3 (GE Healthcare).
BeadChips were scanned with an Illumina BeadArray
Reader. Data was generated from Imagedata using Illumina
software, GenomeStudio. Normalised data was generated
using 3Cubic Spline2 Model in software. Pathway analysis
was performed with Ingenuity Pathway Analysis (IPA, In-
genuity® Systems, www.ingenuity.com) and GeneMANIA
(http://www.genemania.org).
Proteomic analysis
Proteins from serum was extracted and prepared as pre-
viously described [75–77], and the extracted peptides
was analysed using a RSLC 3000 nanoscale capillary LC
followed by qTOF mass spectrometry (5600 Triple-TOF,
Sciex). Sequential window acquisition of all theoretical
spectra (SWATH) was used to profile all proteins in
each sample using a data-independent acquisition
method [78]. ProteinPilot™ was used for protein identifi-
cation and quantitation, as well as visualising peptide-
protein associations and relationships.
Choline extraction
Serum samples were analysed using tandem mass spectrom-
etry (LC-MS/MS) and a multiple-reaction monitoring
(MRM) methodology. Five microliters of serum was ex-
tracted with 90 μL of an organic solution (10% methanol and
90% acetonitrile), containing the deuterium-labelled internal
standard (IS, D9-Cho at 10 μg/mL). This resulted in precipi-
tation of proteins, which were removed by filtration with a
Millex 0.45-μm filter followed by centrifugation for 2min at
6000g. The mass transitions used to measure the analytes are
choline (mass transition m/z 104→ 60) and D9-choline
(mass transition m/z 113→ 69). A QTRAP 5500 triple-
quadrupole mass spectrometer (AB Sciex, Warrington,
Cheshire, UK) with ESI ion source was used for data acquisi-
tion. Separation of analytes was performed in an Acquity
UPLC-MS/MS (Waters, Hertfordshire, UK), with a binary
pump system at a flow rate of 0.3mL/min, connected to the
mass spectrometer. The injection volume was 10 μL. Samples
were separated using a Cogent 100mm×2.1mm, 4 μm Dia-
mond Hydride silica column (Microsolv Technologies, NJ,
USA) and a linear gradient from 65% buffer B (0.1% formic
acid in Acetronitrile) and 35% buffer A (0.1% formic acid in
water) to 35% buffer B over 7min. Analyst software (AB
SCIEX) was used for HPLC system control, data acquisition
and data processing.
Statistics
The data were analysed using various statistical models.
All data were analysed for normal distribution within
each experimental group using the Shapiro–Wilk nor-
mality test. Linear regression and correlation analysis
based on Excel (Microsoft Office 10) built-in functions
with interval of confidence and testing of the correlation
coefficients were performed according to standard pro-
cedures. The SAS software was used to fit the general-
ised linear model (Microsoft Office 10). Normally
distributed data were analysed by ANOVA or t tests, as
appropriate. Where data were not normally distributed,
non-parametric tests were used. When appropriate, P
values were adjusted for multiple comparisons. Data are
presented as histograms (means ± standard error) or
box and whisker plots (boxes indicate the 25th and 75th
percentiles; whiskers display the range; and horizontal
lines in each box represent the median). Regression and
correlation coefficients are given with the intervals of
confidence (p = 0.05). Statistical analyses were performed
using Sigma Plot software (v 11.0) (Systat Software Inc.,
London, UK) and Prism software (GraphPad, USA). P
value < 0.05 was considered statistically significant.
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Additional file 1: Fig. S1. Ambulatory activity of WT and Phospho1−/−
mice. (a) Total activity, (b) fast activity, (c) slow activity, (d) total static
counts, (e) fast static counts, (f) slow static counts, (g) total mobile
counts, (h) fast mobile counts, (i) slow mobile counts, (j) active time, (k)
static time (l) mobile time, (m) front to back, (n) inactive time, (o)
Table 2 Antibodies used for Western blotting
Protein Species Source Catalogue Number Dilution Band size (kDa)
PHOSPHO1 Human AbD Serotec HCA093 1:1000 30
UCP1 Rabbit Cell Signaling #14670 1:1000 32
β-actin (HRP-linked) Mouse Sigma A3854 1:50,000 45
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distance travelled. Data are represented as mean ± S.E.M (n = 6 replicates).
*p < 0.05.
Additional file 2: Fig. S2. Fasted glucose levels of 120 day old WT and
Phospho1−/− mice on the control and HFD. Different letters above the
error bar show significant difference at p < 0.05.
Additional file 3: Fig. S3. μMRI adipose quantification from WT and
Phospho1−/− mice on both a control and HFD. (a) Representative
reconstructed μMRI scan. Green = subcutaneous adipose tissue, Red =
mesenteric adipose tissue, Blue = brown adipose tissue. (b) Inguinal WAT
(iWAT), mesenteric WAT (mWAT) and brown adipose tissue (BAT) mass
determined by μMRI. Results were normalised to body weight (mg/g).
Data are represented as mean ± S.E.M (n = 3 replicates). Different letters
above the error bar show significant difference at p < 0.05.
Additional file 4: Fig. S4. Marrow adipose tissue μCT osmium
quantification. (a) Region-specific quantification of tibial marrow adipose
tissue (MAT) volume. Regions include the proximal epiphysis (Prox Epi),
the growth plate to the tibia/fibula (Tib/Fib) junction (GP to T/F J) and
the tibia/fibula junction to the end of the bone (T/F J to end). (b) Repre-
sentative images of osmium-stained tibiae scanned by μCT. Marrow fat is
dark grey and bone is light grey. Data are represented as mean ± S.E.M
(n = 3 replicates). * p < 0.05, ** p < 0.01.
Additional file 5: Fig. S5. Seahorse analysis of WT and Phospho1−/−
osteoblasts. (a - b) Oxygen consumption rates (OCR) and extracellular
acidification rates (ECAR) using the Seahorse X-24 analyser in WT and
Phospho1−/− primary calvarial osteoblasts cultured in growth media and
growth media supplemented with osteogenic differentiation media for 3
days following a Mito Stress Test. Data represented as means ±S.E.M from
average of two independent seahorse runs, with n = 5 wells per group.
**p < 0.01, ***p < 0.001.
Additional file 6: Table S6. Osteoblast microarray candidates involved
associated with glucose homeostasis. 21 genes from the WT and
Phospho1−/− osteoblast microarray were identified by Ingenuity Pathway
Analysis to be associated with glucose homeostasis p = 1.04 × 10− 6.
Additional file 7: Table S7. In Silico analysis of Ingenuity pathways
predictions In Silico analysis of genes predicated to be associated with
bone and diabetes mellitus.
Additional file 8: Fig. S8 GeneMANIA network summary predictions
GeneMANIA network generated using Ingenuity Pathways Analysis gene
predictions. The network highlights potential interactions between
Phospho1 and related osteoblast genes involved in the glucose metabolic
process, encompassing; glucose transport, insulin receptor signalling,
response to insulin and cellular response to insulin stimulus. Query genes
(black) with the exception of Spic and Runx2 which were inputted
manually, other genes (grey) were generated by the programme using a
large set of inbuilt functional association data. Node size are based on
GO terms. Network line colour corresponds to interaction: purple = co-
expression, pink = physical interactions, blue = co-localisation, green =
shared protein domains orange = predicted, grey = other.
Additional file 9: Table S9. In Silico analysis top diseases associated
with unique WT HFD and Phospho1−/− HFD proteins. (CSV 3 kb)
Additional file 10: Fig. S10. Gene and protein expression of Phospho1
mRNA and PHOSPHO1 protein in murine tissue (a) RT-qPCR of Phospho1
in murine tissues, high expression was seen in the gonad and brown adi-
pose tissue (BAT) (b) Protein expression of PHOSPHO1 was detectable by
western blot in the calvaria and bone. Non-specific binding of the PHOS-
PHO1 antibody was observed in the pancreas, seen in both WT and Phos-
pho1−/− pancreatic tissue.
Additional file 11. Raw data.
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